Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases.
Identifieur interne : 001256 ( Main/Exploration ); précédent : 001255; suivant : 001257Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases.
Auteurs : Mohammed Khalid [Arabie saoudite] ; Fahad Al Rabiah ; Basha Khan ; Abdullah Al Mobeireek ; Taimur S. Butt ; Eid Al MutairySource :
- Antiviral therapy [ 2040-2058 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antiviraux (usage thérapeutique), Charge virale (), Coronavirus du syndrome respiratoire du Moyen-Orient (), Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité), Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie), Femelle, Humains, Infections à coronavirus (), Infections à coronavirus (anatomopathologie), Infections à coronavirus (imagerie diagnostique), Infections à coronavirus (traitement médicamenteux), Interféron alpha (usage thérapeutique), Mâle, Polyéthylène glycols (usage thérapeutique), Protéines recombinantes (usage thérapeutique), Radiographie, Ribavirine (usage thérapeutique).
- MESH :
- anatomopathologie : Infections à coronavirus.
- imagerie diagnostique : Infections à coronavirus.
- pathogénicité : Coronavirus du syndrome respiratoire du Moyen-Orient.
- physiologie : Coronavirus du syndrome respiratoire du Moyen-Orient.
- traitement médicamenteux : Infections à coronavirus.
- usage thérapeutique : Antiviraux, Interféron alpha, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- Adulte, Adulte d'âge moyen, Charge virale, Coronavirus du syndrome respiratoire du Moyen-Orient, Femelle, Humains, Infections à coronavirus, Mâle, Radiographie.
English descriptors
- KwdEn :
- Adult, Antiviral Agents (therapeutic use), Coronavirus Infections (diagnostic imaging), Coronavirus Infections (drug therapy), Coronavirus Infections (pathology), Coronavirus Infections (prevention & control), Female, Humans, Interferon alpha-2, Interferon-alpha (therapeutic use), Male, Middle Aged, Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (pathogenicity), Middle East Respiratory Syndrome Coronavirus (physiology), Polyethylene Glycols (therapeutic use), Radiography, Recombinant Proteins (therapeutic use), Ribavirin (therapeutic use), Viral Load (drug effects).
- MESH :
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- diagnostic imaging : Coronavirus Infections.
- drug effects : Middle East Respiratory Syndrome Coronavirus, Viral Load.
- drug therapy : Coronavirus Infections.
- pathogenicity : Middle East Respiratory Syndrome Coronavirus.
- pathology : Coronavirus Infections.
- physiology : Middle East Respiratory Syndrome Coronavirus.
- prevention & control : Coronavirus Infections.
- Adult, Female, Humans, Interferon alpha-2, Male, Middle Aged, Radiography.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly recognized transmissible viral infection with high virulence and case fatality rates for which there is no currently defined primary treatment or prophylaxis. Saudi Arabia has the largest reported number of cases so far. Like severe acute respiratory syndrome (SARS), MERS is caused by a coronavirus. Combination therapy with interferon-α2b and ribavirin has been used successfully as primary treatment and prophylaxis in SARS. Because of similarities between the two coronaviruses, treatment with ribavarin and interferon-α2b has been suggested as a potential therapy for MERS-CoV. Studies in animal models of MERS-CoV have shown the combination of ribavirin and interferon-α2b to be effective both as primary treatment and prophylaxis. In this report, we describe for the first time use of this combination as a primary treatment for a patient with MERS-CoV infection and as prophylaxis for his spouse and discuss its possible role.
DOI: 10.3851/IMP2792
PubMed: 24831606
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F98
- to stream PubMed, to step Curation: 000F98
- to stream PubMed, to step Checkpoint: 000D70
- to stream Ncbi, to step Merge: 002884
- to stream Ncbi, to step Curation: 002884
- to stream Ncbi, to step Checkpoint: 002884
- to stream Main, to step Merge: 001258
- to stream Main, to step Curation: 001256
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases.</title><author><name sortKey="Khalid, Mohammed" sort="Khalid, Mohammed" uniqKey="Khalid M" first="Mohammed" last="Khalid">Mohammed Khalid</name><affiliation wicri:level="1"><nlm:affiliation>Section of Pulmonary Medicine, King Faisal Hospital and Research Centre, Riyadh, Saudi Arabia. mariamskh2@yahoo.com.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Section of Pulmonary Medicine, King Faisal Hospital and Research Centre, Riyadh</wicri:regionArea><wicri:noRegion>Riyadh</wicri:noRegion></affiliation></author><author><name sortKey="Al Rabiah, Fahad" sort="Al Rabiah, Fahad" uniqKey="Al Rabiah F" first="Fahad" last="Al Rabiah">Fahad Al Rabiah</name></author><author><name sortKey="Khan, Basha" sort="Khan, Basha" uniqKey="Khan B" first="Basha" last="Khan">Basha Khan</name></author><author><name sortKey="Al Mobeireek, Abdullah" sort="Al Mobeireek, Abdullah" uniqKey="Al Mobeireek A" first="Abdullah" last="Al Mobeireek">Abdullah Al Mobeireek</name></author><author><name sortKey="Butt, Taimur S" sort="Butt, Taimur S" uniqKey="Butt T" first="Taimur S" last="Butt">Taimur S. Butt</name></author><author><name sortKey="Al Mutairy, Eid" sort="Al Mutairy, Eid" uniqKey="Al Mutairy E" first="Eid" last="Al Mutairy">Eid Al Mutairy</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:24831606</idno><idno type="pmid">24831606</idno><idno type="doi">10.3851/IMP2792</idno><idno type="wicri:Area/PubMed/Corpus">000F98</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F98</idno><idno type="wicri:Area/PubMed/Curation">000F98</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F98</idno><idno type="wicri:Area/PubMed/Checkpoint">000D70</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D70</idno><idno type="wicri:Area/Ncbi/Merge">002884</idno><idno type="wicri:Area/Ncbi/Curation">002884</idno><idno type="wicri:Area/Ncbi/Checkpoint">002884</idno><idno type="wicri:Area/Main/Merge">001258</idno><idno type="wicri:Area/Main/Curation">001256</idno><idno type="wicri:Area/Main/Exploration">001256</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases.</title><author><name sortKey="Khalid, Mohammed" sort="Khalid, Mohammed" uniqKey="Khalid M" first="Mohammed" last="Khalid">Mohammed Khalid</name><affiliation wicri:level="1"><nlm:affiliation>Section of Pulmonary Medicine, King Faisal Hospital and Research Centre, Riyadh, Saudi Arabia. mariamskh2@yahoo.com.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Section of Pulmonary Medicine, King Faisal Hospital and Research Centre, Riyadh</wicri:regionArea><wicri:noRegion>Riyadh</wicri:noRegion></affiliation></author><author><name sortKey="Al Rabiah, Fahad" sort="Al Rabiah, Fahad" uniqKey="Al Rabiah F" first="Fahad" last="Al Rabiah">Fahad Al Rabiah</name></author><author><name sortKey="Khan, Basha" sort="Khan, Basha" uniqKey="Khan B" first="Basha" last="Khan">Basha Khan</name></author><author><name sortKey="Al Mobeireek, Abdullah" sort="Al Mobeireek, Abdullah" uniqKey="Al Mobeireek A" first="Abdullah" last="Al Mobeireek">Abdullah Al Mobeireek</name></author><author><name sortKey="Butt, Taimur S" sort="Butt, Taimur S" uniqKey="Butt T" first="Taimur S" last="Butt">Taimur S. Butt</name></author><author><name sortKey="Al Mutairy, Eid" sort="Al Mutairy, Eid" uniqKey="Al Mutairy E" first="Eid" last="Al Mutairy">Eid Al Mutairy</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="eISSN">2040-2058</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiviral Agents (therapeutic use)</term><term>Coronavirus Infections (diagnostic imaging)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (pathology)</term><term>Coronavirus Infections (prevention & control)</term><term>Female</term><term>Humans</term><term>Interferon alpha-2</term><term>Interferon-alpha (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term><term>Middle East Respiratory Syndrome Coronavirus (pathogenicity)</term><term>Middle East Respiratory Syndrome Coronavirus (physiology)</term><term>Polyethylene Glycols (therapeutic use)</term><term>Radiography</term><term>Recombinant Proteins (therapeutic use)</term><term>Ribavirin (therapeutic use)</term><term>Viral Load (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (usage thérapeutique)</term><term>Charge virale ()</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie)</term><term>Femelle</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (anatomopathologie)</term><term>Infections à coronavirus (imagerie diagnostique)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Interféron alpha (usage thérapeutique)</term><term>Mâle</term><term>Polyéthylène glycols (usage thérapeutique)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Radiographie</term><term>Ribavirine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term><term>Viral Load</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Interferon alpha-2</term><term>Male</term><term>Middle Aged</term><term>Radiography</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Charge virale</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Femelle</term><term>Humains</term><term>Infections à coronavirus</term><term>Mâle</term><term>Radiographie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly recognized transmissible viral infection with high virulence and case fatality rates for which there is no currently defined primary treatment or prophylaxis. Saudi Arabia has the largest reported number of cases so far. Like severe acute respiratory syndrome (SARS), MERS is caused by a coronavirus. Combination therapy with interferon-α2b and ribavirin has been used successfully as primary treatment and prophylaxis in SARS. Because of similarities between the two coronaviruses, treatment with ribavarin and interferon-α2b has been suggested as a potential therapy for MERS-CoV. Studies in animal models of MERS-CoV have shown the combination of ribavirin and interferon-α2b to be effective both as primary treatment and prophylaxis. In this report, we describe for the first time use of this combination as a primary treatment for a patient with MERS-CoV infection and as prophylaxis for his spouse and discuss its possible role. </div></front></TEI><affiliations><list><country><li>Arabie saoudite</li></country></list><tree><noCountry><name sortKey="Al Mobeireek, Abdullah" sort="Al Mobeireek, Abdullah" uniqKey="Al Mobeireek A" first="Abdullah" last="Al Mobeireek">Abdullah Al Mobeireek</name><name sortKey="Al Mutairy, Eid" sort="Al Mutairy, Eid" uniqKey="Al Mutairy E" first="Eid" last="Al Mutairy">Eid Al Mutairy</name><name sortKey="Al Rabiah, Fahad" sort="Al Rabiah, Fahad" uniqKey="Al Rabiah F" first="Fahad" last="Al Rabiah">Fahad Al Rabiah</name><name sortKey="Butt, Taimur S" sort="Butt, Taimur S" uniqKey="Butt T" first="Taimur S" last="Butt">Taimur S. Butt</name><name sortKey="Khan, Basha" sort="Khan, Basha" uniqKey="Khan B" first="Basha" last="Khan">Basha Khan</name></noCountry><country name="Arabie saoudite"><noRegion><name sortKey="Khalid, Mohammed" sort="Khalid, Mohammed" uniqKey="Khalid M" first="Mohammed" last="Khalid">Mohammed Khalid</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001256 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001256 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24831606
|texte= Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24831606" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |